Wedbush downgraded Fusion Pharmaceuticals (FUSN) to Neutral from Outperform with a price target of $24, up from $13, after the company agreed acquired by AstraZeneca (AZN) for $21 per share in cash at closing plus a non-transferrable contingent value right of $3.00 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FUSN:
- Fusion Pharmaceuticals’ Acquisition and Future Focus Shift
- Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
- Fusion Pharmaceuticals Inc (FUSN) Q4 Earnings Cheat Sheet
- 3 Best Stocks to Buy Now, 3/5/2024, According to Top Analysts
- Fusion Pharmaceuticals price target raised to $16 from $12 at RBC Capital
